Inhibition of IRE1α RNase activity sensitizes patient‐derived acute myeloid leukaemia cells to proteasome inhibitors.

Autor:	Creedican, Stuart, Robinson, Claire M., Mnich, Katarzyna, Islam, Md Nahidul, Szegezdi, Eva, Clifford, Ruth, Krawczyk, Janusz, Patterson, John B., FitzGerald, Stephen P., Summers, Mark, Richardson, Ciaran, Martin, Kenneth, Gorman, Adrienne M., Samali, Afshin
Předmět:	ACUTE myeloid leukemia MYELOID cells PROTEASOME inhibitors MULTIPLE myeloma PROTEASOMES CHRONIC myeloid leukemia
Zdroj:	Journal of Cellular & Molecular Medicine; Aug2022, Vol. 26 Issue 16, p4629-4633, 5p
Abstrakt:	Inhibition of IRE1 RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors The cells that were most responsive to MKC8866 plus CFZ co-treatment when compared with CFZ treatment alone had the highest XBP1s and vice versa. Significantly increased AML cell death was observed in the combination treatments that included CFZ ( I p i < 0.0001); increased cell death was observed in the combination treatments with BTZ but this was not significant (Figure 1D,E, right panels). We demonstrate that an IRE1 RNase inhibitor (MKC8866), in combination with proteasome inhibitors, significantly decreases XBP1s levels and increases cell death in AML cell lines and patient-derived AML cells. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text